Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

INOVIO PHA Form 4 May 08, 2015	ARMACEUTICA	LS, INC	· · ·								
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF							OMB Number: Expires:	PPROVAL 3235-0287 January 31, 2005			
Section 10 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	6. Filed purs ¹⁸ Section 17(a) of the I	Public Uti		Securiti	pany	Act o	ge Act of 1934, f 1935 or Sectic 40	Estimated a burden hou response	irs per	
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> DHILLON AVTAR S			2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [INO]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 660 W. GERMANTOWN PIKE, SUITE 100			3. Date of Earliest Transaction (Month/Day/Year) 05/08/2015					X_Director10% Owner Officer (give titleOther (specify below) below)			
				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State) (2	Zip)	Table	I - Non-De	erivative S	ecurit	ies Ac	quired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any	on Date, if TransactionAc Code Di		onAcquired Disposed	Securities cquired (A) or isposed of (D) nstr. 3, 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock				Code V	Amount	(D)	Price	(Instr. 3 and 4) 58,333	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Exercise any ee of (Month ivative		4. Transactio Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amoun or Number of Shares
Restricted Stock Unit	<u>(1)</u>	05/08/2015		А	5,000	<u>(1)</u>	(1)	Common Stock	5,000
Common Stock Option	\$ 8.01	05/08/2015		А	7,500	05/08/2016 <u>(2)</u>	05/08/2025	Common Stock	7,500

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

Reporting Owners

Reporting Owner Na	Relationships					
reporting o whet i w	reporting o where reader that ess			Officer	Other	
DHILLON AVTAR S 660 W. GERMANTOWN PLYMOUTH MEETING,	Х					
Signatures						
Avtar S. Dhillon	05/08/2015					
<u>**</u> Signature of	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 8, 2016. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
- (2) Options to vest 100% on May 8, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Person